Stock listing

ASX:SOM Somnomed Limited Share Price

Home listing (ASX) of Somnomed Limited

Follow Somnomed Limited into a list and get an email when it puts out news.

Share price · ASX:SOM

$0.31 AUD 0.00 (0.0%)

Close on Nov 20, 2026

Past year -60.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.31 – $0.31 AUDNov 20, 2026
Volume
88,000 sharesNov 20, 2026
Market cap
$68.13M AUDAt the close on Nov 20, 2026 · price × 219.8M shares outstanding
52-week range
$0.23 – $0.81 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$24,902 AUDMedian day 31,106 shares · 14 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Somnomed Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:SOM · Home$0.31 AUD0.00 (0.0%)88,000$0.31$0.31$0.31$0.31Close on Nov 20, 2026
OTC:SOMNF$0.18 USD0.00 (0.0%)—$0.18$0.18$0.18$0.18Close on Nov 10, 2026
Frankfurt:RJV€0.174 EUR-0.001 (-0.6%)—€0.175€0.175€0.174€0.175Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:SOM · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.310.000.0%$0.31$0.31$0.3188,000
$0.31+0.01+3.3%$0.30$0.31$0.272,050,672
$0.300.000.0%$0.30$0.30$0.300
$0.30-0.01-3.2%$0.30$0.30$0.3035,031
$0.31-0.01-3.1%$0.31$0.31$0.3110,000
$0.32+0.03+10.3%$0.32$0.32$0.3123,544
$0.290.000.0%$0.29$0.29$0.290
$0.290.000.0%$0.29$0.29$0.291,293
$0.29+0.01+3.6%$0.29$0.29$0.297,000
$0.28-0.01-3.4%$0.30$0.30$0.2813,187
$0.29-0.02-6.5%$0.32$0.32$0.292,876
$0.31+0.01+3.3%$0.30$0.31$0.29557,171
$0.300.000.0%$0.30$0.30$0.29562,074
$0.30+0.01+3.4%$0.305$0.305$0.29104,243
$0.290.000.0%$0.29$0.29$0.2919,602
$0.29-0.01-3.3%$0.305$0.305$0.2976,669
$0.300.000.0%$0.30$0.30$0.3020,000
$0.300.000.0%$0.30$0.31$0.29127,529
$0.30+0.01+3.4%$0.295$0.30$0.2967,226
$0.29+0.005+1.8%$0.29$0.29$0.292,500
$0.285-0.005-1.7%$0.29$0.29$0.28167,375
$0.290.000.0%$0.29$0.29$0.2860,861
$0.29+0.055+23.4%$0.27$0.29$0.2755,194
$0.2350.000.0%$0.235$0.235$0.2350
$0.2350.000.0%$0.235$0.235$0.2350
$0.235-0.015-6.0%$0.23$0.25$0.23204,946
$0.25-0.02-7.4%$0.275$0.275$0.2567,786
$0.27+0.01+3.8%$0.275$0.28$0.27185,975
$0.26-0.01-3.7%$0.265$0.27$0.2637,844
$0.27-0.005-1.8%$0.27$0.27$0.2711,507
$0.275-0.015-5.2%$0.28$0.28$0.27525,722
$0.290.000.0%$0.285$0.29$0.27100,011
$0.290.000.0%$0.29$0.29$0.290
$0.290.000.0%$0.29$0.29$0.290
$0.290.000.0%$0.29$0.29$0.290
$0.29-0.025-7.9%$0.30$0.30$0.2962,956
$0.315+0.02+6.8%$0.30$0.315$0.3041,269
$0.295+0.005+1.7%$0.295$0.295$0.29529,998
$0.29-0.02-6.5%$0.31$0.31$0.2923,625
$0.31-0.01-3.1%$0.32$0.32$0.3043,757
$0.32-0.005-1.5%$0.30$0.32$0.3084,605
$0.3250.000.0%$0.325$0.325$0.3250
$0.325-0.005-1.5%$0.33$0.33$0.325103,916
$0.330.000.0%$0.33$0.33$0.330
$0.33-0.01-2.9%$0.34$0.34$0.3358,800
$0.34-0.01-2.9%$0.335$0.34$0.3380,799
$0.350.000.0%$0.35$0.35$0.350
$0.35+0.015+4.5%$0.33$0.35$0.3331,106
$0.335+0.015+4.7%$0.32$0.335$0.32288,564
$0.32-0.01-3.0%$0.33$0.335$0.32224,575
$0.33-0.005-1.5%$0.34$0.34$0.3377,725
$0.335-0.01-2.9%$0.345$0.345$0.33577,449
$0.3450.000.0%$0.36$0.36$0.3453,481
$0.3450.000.0%$0.345$0.345$0.3450
$0.3450.000.0%$0.345$0.345$0.3450
$0.3450.000.0%$0.345$0.345$0.3450
$0.345-0.01-2.8%$0.345$0.345$0.3452,374
$0.355+0.02+6.0%$0.335$0.355$0.335109,240
$0.3350.000.0%$0.315$0.335$0.31510,725
$0.3350.000.0%$0.33$0.335$0.30112,750
$0.335+0.005+1.5%$0.345$0.345$0.33512,441
$0.330.000.0%$0.33$0.33$0.330
$0.33-0.01-2.9%$0.335$0.335$0.334,837
$0.34-0.005-1.4%$0.345$0.345$0.3463,599
$0.345-0.01-2.8%$0.355$0.355$0.34547,786
$0.355-0.01-2.7%$0.355$0.355$0.3526,918
$0.3650.000.0%$0.355$0.37$0.3599,013

Splits

1 split · ASX:SOM · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
ASX:SOM
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
ASX
Currency
AUD

What changed lately

Latest news

Change in substantial holding

Nov 19, 2026

Closed $0.31 (0.0%) on Nov 20, 2026

Annual General Meeting Proxy Form

Oct 16, 2026

Closed $0.235 (0.0%) on Oct 19, 2026

Notice of Annual General Meeting

Oct 16, 2026

Closed $0.235 (0.0%) on Oct 19, 2026

Chair Transition

Oct 16, 2026

Closed $0.235 (0.0%) on Oct 19, 2026

Change of Director's Interest Notice

Aug 28, 2026

Closed $0.335 (0.0%) on Aug 31, 2026

Full year results announcement FY26

Aug 27, 2026

Closed $0.335 (+1.5%) on Aug 28, 2026

Full Year Statutory Accounts

Aug 27, 2026

Closed $0.335 (+1.5%) on Aug 28, 2026

Securities Trading Policy

Aug 27, 2026

Closed $0.335 (+1.5%) on Aug 28, 2026

Corporate Governance Statement

Aug 27, 2026

Closed $0.335 (+1.5%) on Aug 28, 2026

All Somnomed Limited news

Somnomed Limited on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
24 in the last 12 months · 178 in all · newest Nov 20, 2026 · oldest 2016
Decks
55 decks · latest Aug 28, 2026

Where Somnomed Limited is listed

ListingExchangeCountryCurrency
ASX:SOM · Home listing · This pageASXAustraliaAUD
LS Exchange:A0B7QALS ExchangeGermanyEUR
Lang & Schwarz:A0B7QALang & SchwarzGermanyEUR
gettex:RJVgettexGermanyEUR
OTC:SOMNFOTCUnited StatesUSD
Dusseldorf:RJVDusseldorfGermanyEUR
Frankfurt:RJVFrankfurtGermanyEUR
Munich:RJVMunichGermanyEUR
Stuttgart:RJVStuttgartGermanyEUR
Tradegate:RJVTradegateGermanyEUR

Valuation

EV/sales 0.5× against a median of 2.9×: 3rd lowest of 10 Medical devices & supplies companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$56.40M AUD
P/E
Loss
EV/sales
0.5×
EV/EBITDA
8.7×
Price/book
1.4×
Gross margin
53.2%
Operating margin
0.9%
Net margin
−2.3%
Debt to equity
0.1×
Beta
No index for this market yet

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Somnomed Limited · ASX:SOMUS$45.09MUS$37.33Mn/a0.5×8.7×1.4×−2.3%0.1×n/a
Medimaging Integrated Solution Inc. · TWSE:6796US$48.03MUS$43.05M111×2.1×28.6×1.9×2.1%0.5×n/a
Conexeu Sciences Inc. · NASDAQ:CNXUUS$47.79MUS$45.82Mn/an/an/a8.2×n/a0.0×2.08
Microbot Medical Inc. · NASDAQ:MBOTUS$45.67M−US$16.16Mn/a−38.6×n/a0.7×n/a0.0×1.82
RenovoRx, Inc. · NASDAQ:RNXTUS$45.45MUS$35.27Mn/a12.7×n/a4.9×−469.0%0.0×1.71
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. · BIST:ONCSMUS$45.25MUS$45.28M31.7×2.9×7.5×4.5×9.0%0.1×n/a
Bactiguard Holding AB · OMXSTO:BACTI_BUS$45.14MUS$54.81M76.6×2.6×12.5×1.5×2.8%0.5×n/a
Nuo Therapeutics Inc · OTC:AURXUS$44.38MUS$44.30Mn/a7.3×n/an/a−31.5%n/a0.73
Ortoma AB Class B · OMXSTO:ORT_BUS$44.27MUS$38.13Mn/a11.7×n/a2.6×−197.7%0.0×n/a
BrainCool AB · OMXSTO:BRAINUS$43.31MUS$39.09Mn/a9.8×n/a2.8×−84.7%0.0×n/a
Corentec Co., Ltd. · KRX:104540US$42.58MUS$24.07M8.5×0.3×2.3×0.7×6.4%0.0×n/a
Median of the othersUS$45.20MUS$41.07M54.1×2.9×10.0×2.6×−14.7%0.0×1.77

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
0.84 AUD · Analysts' mean
EPS, year to Jun 2027
0.020 · 2 analysts
Revenue, year to Jun 2027
121.9M · 3 analysts

Team and board

Officers

OfficerRole
Karen BorgChief Executive Officer and Executive Director
Terence FlitcroftCompany Secretary
Alison BellSales Manager | UK

Board

DirectorRole
Andrew PriceNon-Executive Director
Benjamin GiszNon-Executive Director
Karen BorgChief Executive Officer and Executive Director
Michael GordonNon-Executive Director

Events

QuarterResultsShare move
Quarter to Mar 31, 2026Apr 29, 2026−2.6%
Quarter to Sep 30, 2025Dec 3, 2025−1.2%
Q4 2025Aug 27, 2025+8.2%
Quarter to Mar 31, 2025May 30, 2025+4.8%
Q2 2025Feb 27, 20250.0%
Quarter to Sep 30, 2024Nov 27, 2024+46.3%
Q4 2024Aug 27, 2024−2.5%
Quarter to Mar 31, 2024Jun 27, 2024 · Before open0.0%
Q2 2024Feb 27, 2024+2.6%
Quarter to Sep 30, 2023Oct 30, 2023 · After close0.0%
All 20 quarters
QuarterResultsShare move
Q4 2023Aug 31, 2023 · After close0.0%
Q3 2023Apr 28, 2023 · Before open0.0%
Q2 2023Feb 22, 2023−13.1%
Q1 2023Oct 25, 2022 · Before open+3.5%
Q4 2022Aug 23, 2022 · Before open−0.8%
Q3 2022Apr 26, 20220.0%
Q2 2022Feb 21, 2022 · After close−2.1%
Q1 2022Dec 1, 2021+1.4%
Q4 2021Aug 23, 20210.0%
Q3 2021Jun 2, 2021+6.1%

Open Events

Decks

DeckKindSlidesDate
FY2026 Earnings PresentationEarnings21 slidesAug 28, 2026
Investor Presentation (February 2026)Investor deck20 slidesFeb 27, 2026
Shareholder Meeting (November 2025)Shareholder meeting12 slidesNov 27, 2025
Canaccord Drug & Devices Conference 2025Conference9 slidesOct 21, 2025
FY2025 Earnings PresentationEarnings21 slidesAugust 2025
H1 FY25 Earnings PresentationEarnings19 slidesFebruary 2025
Shareholder Meeting (November 2024)Shareholder meeting11 slidesNov 27, 2024
Investor Presentation (August 2024)Investor deck19 slidesAug 28, 2024
Investor Presentation (April 2024)Investor deck16 slidesApr 9, 2024
H1 2024 Earnings PresentationEarnings24 slidesFebruary 2024
Show 50 decks
DeckKindSlidesDate
Investor Presentation (2024)Investor deck7 slides2024
Shareholder Meeting (November 2023)Shareholder meeting16 slidesNov 24, 2023
Wilsons Drug and Device Conference 2023Conference9 slidesOct 26, 2023
FY2023 Earnings PresentationEarnings43 slidesAugust 2023
H1 FY2023 Earnings PresentationEarnings23 slidesFeb 22, 2023
Shareholder Meeting (2023)Shareholder meeting7 slides2023
Shareholder Meeting (November 2022)Shareholder meeting22 slidesNov 25, 2022
FY2022 Earnings PresentationEarnings26 slidesAug 23, 2022
H1 FY2022 Earnings PresentationEarnings30 slidesFebruary 2022
Shareholder Meeting (November 2021)Shareholder meeting18 slidesNov 25, 2021
FY2021 Earnings PresentationEarnings29 slidesAug 24, 2021
H1 FY2021 Earnings PresentationEarnings27 slidesFeb 23, 2021
H1 FY2021 Earnings PresentationEarnings27 slides2021
Shareholder Meeting (November 2020)Shareholder meeting22 slidesNov 26, 2020
FY2020 Earnings PresentationEarnings30 slidesAug 24, 2020
Investor Presentation (March 2020)Investor deck22 slidesMar 25, 2020
H1 FY2020 Earnings PresentationEarnings25 slidesFeb 18, 2020
Investor Presentation (2020)Investor deck30 slides2020
Investor Presentation (August 2019)Investor deck27 slidesAug 21, 2019
H1 FY2019 Earnings PresentationEarnings19 slidesFeb 21, 2019
Investor Presentation (August 2018)Investor deck22 slidesAug 22, 2018
H1 2017/18 Earnings PresentationEarnings25 slidesFeb 19, 2018
Investor Presentation (August 2017)Investor deck12 slidesAug 24, 2017
H1 FY2016/17 Earnings PresentationEarnings11 slidesFeb 23, 2017
Investor Presentation (August 2016)Investor deck12 slidesAug 18, 2016
Investor Presentation (May 2016)Investor deck17 slidesMay 3, 2016
H1 FY2016 Earnings PresentationEarnings14 slidesFeb 18, 2016
Investor Presentation (August 2015)Investor deck13 slidesAug 20, 2015
H1 FY2015 Earnings PresentationEarnings12 slidesFeb 18, 2015
Investor Presentation (November 2014)Investor deck7 slidesNov 10, 2014
Investor Presentation (August 2014)Investor deck16 slidesAug 21, 2014
H1 FY2014 Earnings PresentationEarnings14 slidesFeb 26, 2014
Investor Presentation (September 2013)Investor deck14 slidesSep 25, 2013
H1 FY2013 Earnings PresentationEarnings13 slidesFeb 28, 2013
Investor Presentation (August 2012)Investor deck16 slidesAug 31, 2012
H1 FY2012 Earnings PresentationEarnings14 slidesFeb 27, 2012
FY2011 Earnings PresentationEarnings16 slidesAug 29, 2011
Investor Presentation (February 2011)Investor deck13 slidesFeb 28, 2011
Investor Presentation (September 2010)Investor deck16 slidesSep 2, 2010
Investor Presentation (September 2009)Investor deck19 slidesSep 7, 2009

This page holds 50 of 55 decks. Open Decks

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue114.5M111.5M91.7M83.6M72.6M62.7M57.3M58.9M52.4M49.3M
Cost of revenue53.6M44.8M36.5M37.8M33.4M28.8M27.3M24.3M20.5M20.5M
Gross profit60.9M66.7M55.1M45.8M39.2M33.9M30.0M34.6M31.9M28.8M
Research and development1.74M1.82M1.04M705.9K978.4K958.2K904.3K1.06M949.1K953.7K
Selling, general and administrative46.2M20.2M18.0M14.1M13.8M11.2M10.5M12.2M9.38M13.5M
Operating income976.0K3.62M-8.33M-4.07M-4.13M-651.4K-941.0K918.5K2.00M-3.73M
Depreciation and amortization5.49M5.75M5.78M5.12M3.94M3.84M3.09M2.30M1.68M1.23M
EBITDA6.46M9.36M-2.55M1.04M-195.3K3.19M2.14M3.22M3.68M-2.50M
Interest expense464.0K398.5K3.17M2.63M380.3K469.2K473.1K205.3K199.6K20.4K
Income before tax-458.0K-763.9K-11.3M-7.05M-3.50M-733.9K747.0K607.2K1.84M-3.76M
Income tax2.19M2.69M971.1K821.6K930.6K349.2K1.19M646.6K1.61M399.3K
Net income-2.65M-3.46M-12.2M-8.00M-4.44M-1.19M-1.12M-39.4K2.32M-3.34M
Earnings per share, basic-0.01-0.02-0.10-0.10-0.05-0.01-0.02-0.000.04-0.06

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents17.2M17.3M16.2M12.0M15.6M21.1M30.2M7.70M13.4M14.2M
Short-term investments0
Receivables11.6M11.2M7.93M9.03M9.20M8.22M6.13M7.12M10.4M6.62M
Inventory7.36M7.43M6.29M4.10M3.09M2.33M2.24M1.90M2.00M1.95M
Current assets38.9M43.1M35.1M27.5M30.3M34.1M40.2M20.2M29.0M26.4M
Property, plant and equipment13.9M11.1M12.7M9.12M10.3M10.2M3.25M5.69M4.49M
Goodwill6.54M7.05M6.34M6.49M6.04M6.26M6.47M6.41M6.38M6.17M
Total assets75.0M81.0M69.8M62.5M58.1M56.2M61.7M34.8M45.7M41.2M
Accounts payable6.01M19.3M13.1M12.0M12.6M10.3M8.28M7.83M8.08M7.55M
Current liabilities23.3M28.6M19.9M18.4M23.8M16.2M18.8M16.0M11.5M9.95M
Long-term debt311.0K448.6K709.1K16.4M2.01M2.35M2.51M1.04M
Total debt5.46M8.03M6.72M23.5M12.0M8.91M15.5M3.60M1.44M122.5K
Total liabilities27.6M34.6M24.8M40.1M30.3M24.0M27.9M16.9M12.9M10.3M
Shareholders' equity47.4M46.4M45.0M22.4M27.8M32.2M33.8M17.8M36.1M32.2M
Shares outstanding216.3M211.9M120.7M82.1M82.1M82.0M66.0M70.8M55.6M53.7M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations8.28M7.78M-6.33M-3.88M1.86M2.71M5.19M-6.55M-9.47M-2.68M
Capital spending-3.26M-2.42M-1.39M-6.41M-8.79M-4.13M-2.19M-1.34M-2.01M-2.39M
Free cash flow5.02M5.36M-7.72M-10.3M-6.93M-1.43M3.00M-7.89M-11.5M-5.07M
Cash from investing-5.74M-3.98M-5.34M-6.41M-8.47M-4.37M-1.83M-1.63M-2.20M-2.74M
Cash from financing-1.47M-3.38M16.7M6.61M2.09M-6.80M18.9M2.38M10.5M2.28M
Dividends paid-20.1M-4.96M0
Share buybacks-16.0K0-2.07M00399.0K-617.2K-73.5K-371.7K-71.4K
Change in cash-109.4K1.11M4.22M-3.69M-5.47M-9.06M22.5M-5.69M-826.9K-3.42M

Open Financials

Filings

FilingDateTypeFiled with
Change in substantial holdingNov 19, 2026Ownership change noticeASX
Annual General Meeting Proxy FormOct 16, 2026Meeting noticeASX
Notice of Annual General MeetingOct 16, 2026Meeting noticeASX
Chair TransitionOct 16, 2026Other filingsASX
Change in substantial holdingSep 28, 2026Ownership change noticeASX
Notification of cessation of securities - SOMSep 4, 2026FinancingASX
Change of Director's Interest NoticeAug 28, 2026Ownership change noticeASX
Change of Director's Interest NoticeAug 28, 2026Ownership change noticeASX
Change of Director's Interest NoticeAug 28, 2026Ownership change noticeASX
Change of Director's Interest NoticeAug 28, 2026Ownership change noticeASX
All 178 filings
FilingDateTypeFiled with
Full year results announcement FY26Aug 27, 2026ResultsASX
Full Year Statutory AccountsAug 27, 2026Annual reportASX
Securities Trading PolicyAug 27, 2026Other filingsASX
Corporate Governance StatementAug 27, 2026Other filingsASX
Appendix 4GAug 27, 2026Other filingsASX
Investor presentationAug 27, 2026Other filingsASX
Notification of cessation of securities - SOMAug 25, 2026Notification letterASX
FY26 Results announcement date and Webinar InvitationAug 18, 2026Other filingsASX
Securities Trading PolicyAug 14, 2026Other filingsASX
Executive management update & unaudited FY26 resultsJul 27, 2026Other filingsASX
Investor presentationFeb 26, 2026Other filingsASX
Half Yearly Report and AccountsFeb 26, 2026Interim reportASX
Half year results announcement FY26Feb 26, 2026Interim reportASX
AGM Investor Presentation & addressesNov 27, 2025Other filingsASX
Quarterly UpdateOct 29, 2025Other filingsASX
Annual Report & full year resultsAug 27, 2025Annual reportASX
Full year results announcement FY25Aug 27, 2025ResultsASX
Quarterly Cashflow ReportJul 28, 2025Quarterly reportASX
Quarterly Activities ReportJul 28, 2025Quarterly reportASX
United States of America tariff updateApr 7, 2025Other filingsASX
FY25 Half Year ResultsFeb 27, 2025Interim reportASX
Quarterly Appendix 4C Cash Flow ReportJan 23, 2025Quarterly reportASX
FY25 Guidance Update and Quarterly ReportJan 23, 2025Quarterly reportASX
AGM Chairman & co-CEO addressesNov 26, 2024Other filingsASX
Investor Presentation AGMNov 26, 2024Other filingsASX
FY25 Guidance Upgrade and Appointment of CFONov 26, 2024GuidanceASX
Rest Assure - US Food and Drug Authority (FDA) UpdateOct 6, 2024Other filingsASX
Investor PresentationAug 27, 2024Other filingsASX
FY24 Preliminary Report and FY25 GuidanceAug 27, 2024GuidanceASX
Preliminary Final ReportAug 27, 2024ResultsASX
Completion of retail component of Entitlement OfferMay 3, 2024FinancingASX
Replacement ProspectusApr 15, 2024Offer documentASX
Reinstatement to QuotationApr 10, 2024Trading halt or suspensionASX
Completion of institutional component of Entitlement OfferApr 10, 2024FinancingASX
Prospectus Entitlement OfferApr 8, 2024Offer documentASX
Revised guidance and capital raisingApr 8, 2024GuidanceASX
Update on voluntary suspension & FY24 earnings guidanceApr 4, 2024GuidanceASX
Suspension from QuotationApr 2, 2024Trading halt or suspensionASX
Trading HaltMar 26, 2024Trading halt or suspensionASX
Solid start in 1H as core business revenues increase 13%Feb 27, 2024Other filingsASX
Appointment of Co-CEO'sFeb 22, 2024Management or board changeASX
AGM presentationNov 24, 2023Other filingsASX
AGM Chairman & CEO addressesNov 24, 2023Meeting outcomeASX
Quarterly cash reportOct 29, 2023Quarterly reportASX
Results of Retail Entitlement OfferSep 25, 2023FinancingASX
Successful completion of institutional Offer and PlacementSep 3, 2023FinancingASX
FY23 results and Capital raisingAug 30, 2023ResultsASX
Appendix 4CJul 25, 2023Quarterly reportASX
Appendix 4C - March 2023Apr 27, 2023Quarterly reportASX
Growth momentum maintainedApr 27, 2023Other filingsASX
Revenue growth momentum continues in 1H FY23Feb 22, 2023Other filingsASX
Updated Quarterly ActivitiesFeb 1, 2023Quarterly reportASX
Appendix 4C - December 2022Jan 29, 2023Quarterly reportASX
Second quarter revenue growth of 17% to $21.4 millionJan 29, 2023Other filingsASX
AGM Chairman and CEO addressesNov 24, 2022Other filingsASX
AGM Investor PresentationNov 24, 2022Other filingsASX
Appendix 4C....typographical correctionOct 26, 2022Quarterly reportASX
Appendix 4C Cash Flow ReportOct 24, 2022Quarterly reportASX
North America Q1 revenue growth leads the wayOct 24, 2022Other filingsASX
FY22 results and FY23 guidanceAug 22, 2022GuidanceASX
Quarterly Cash Flow ReportJul 25, 2022Quarterly reportASX
Record Q4 and delivers on FY22 revenue guidanceJul 25, 2022GuidanceASX
Strong revenue growth and continued positive momentumApr 26, 2022Other filingsASX
Revenues on track despite COVID-19 disruptionsFeb 21, 2022Other filingsASX
World first technology enabled oral applianceJan 30, 2022Other filingsASX
North America Q2 revenue 36% amid regional variabilityJan 26, 2022Other filingsASX
Quarterly - revenue growth in key markets gains momentumOct 25, 2021Other filingsASX
Appendix 4C - quarterlyJul 26, 2021Quarterly reportASX
Quarterly activities - Strong Q4 provides momentum into FY22Jul 26, 2021Quarterly reportASX
Trading and operational activities improved over the quarterApr 26, 2021Other filingsASX
S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021Other filingsASX
H1 FY21 SomnoMed Media ReleaseFeb 22, 2021Other filingsASX
$17m of revenue delivered for the December Quarter FY21Jan 27, 2021Other filingsASX
AGM Presentation and addressesNov 26, 2020Other filingsASX
Improved quarterly performanceOct 20, 2020Other filingsASX
SomnoMed appoints new DirectorsAug 20, 2020Management or board changeASX
Positive trends for Q4 in the midst of a global pandemicJul 22, 2020Other filingsASX
S&P DJI Announces June 2020 Quarterly RebalanceJun 11, 2020Other filingsASX
Trading updateJun 1, 2020Other filingsASX
Satisfactory Q3 despite COVID-19 affected MarchApr 26, 2020Other filingsASX
Retail Entitlement Offer BookletMar 31, 2020FinancingASX
Reinstatement to Official QuotationMar 25, 2020Trading halt or suspensionASX
Results of Institutional OfferMar 25, 2020Other filingsASX
Trading Update and Entitlement OfferMar 24, 2020FinancingASX
Suspension from Official QuotationMar 18, 2020Trading halt or suspensionASX
Pause in TradingMar 17, 2020Trading halt or suspensionASX
Half Year AccountsFeb 17, 2020Interim reportASX
Core revenue growth up 19% in Q2Jan 27, 2020Other filingsASX
Strong North American revenue growth in Q1Oct 27, 2019Other filingsASX
North American direct revenues up 31% in Q4Jul 23, 2019Other filingsASX
500,000 patients treated worldwideJul 8, 2019Other filingsASX
Core revenue growth up 9% in Q3Apr 28, 2019Other filingsASX
S&P DJI Announces March 2019 Quarterly RebalanceMar 7, 2019Other filingsASX
Core revenue growth up 13% in Q2Jan 28, 2019Other filingsASX
2018 AGM addresses - Chairman and CEONov 26, 2018Other filingsASX
Change in Leadership of SomnoMedNov 18, 2018Other filingsASX
Response to Appendix 4C QueryNov 4, 2018Quarterly reportASX
Strong first quarter in Core business diluted by RSS resultsOct 25, 2018Other filingsASX
Full year results and the consolidation of RSS operationsAug 21, 2018ResultsASX
SomnoMed posts 30% revenue growth for FY2018Jul 24, 2018Other filingsASX
Trading UpdateMay 24, 2018Other filingsASX
Retail Entitlement Offer Information BookletFeb 20, 2018FinancingASX
Successful completion of Institutional Entitlement OfferFeb 20, 2018FinancingASX
Accelerated non-renounceable entitlement offerFeb 18, 2018FinancingASX
ASX Market Release - Trading HaltFeb 18, 2018Trading halt or suspensionASX
Revenue growth up 45% in Q2Jan 23, 2018Other filingsASX
Good revenue growth for the quarterOct 25, 2017Other filingsASX
Strong Q4 growth to finish transitional yearJul 24, 2017Other filingsASX
Renew Sleep Solutions well ahead of planApr 25, 2017Other filingsASX
Renew Sleep Solutions opens first two centres in Q2Jan 22, 2017Other filingsASX
Sales growth acceleratingOct 17, 2016Other filingsASX
FDA 510k approval for SomnoDent AlphaSep 21, 2016Other filingsASX
Strong finish to the financial year for SomnoMedJul 21, 2016Other filingsASX
Derek Smith appointed Global CEO of SomnoMedJul 18, 2016Other filingsASX
Results of Institutional Entitlement OfferMay 4, 2016FinancingASX
Chairmans LetterMay 2, 2016Other filingsASX
Continuing High Growth in the Third QuarterApr 20, 2016Other filingsASX
SomnoMed continues to break records in 4th QuarterMar 30, 2016Other filingsASX
SomnoMed Accelerates Growth beyond ForecastsMar 30, 2016Other filingsASX
SomnoMed posts new record in Q3Mar 30, 2016Other filingsASX
CEO transfers to USMar 30, 2016Other filingsASX
SomnoMed reports solid growth and stronger profitsMar 30, 2016Other filingsASX
SomnoMed finishes year with record quarterMar 30, 2016Other filingsASX
Somnomed expands business and operations in EuropeMar 30, 2016Other filingsASX
Partnership with Sleep HealthCentersMar 30, 2016Other filingsASX
SomnoDent G2 FDA 510(k) clearedMar 30, 2016Other filingsASX
US Medical ExpansionMar 30, 2016Other filingsASX
Strong Global Sales Growth continues in Second QuarterMar 30, 2016Other filingsASX
Acquisition of Dutch Oral Appliance Distribution CompanyMar 30, 2016Acquisition or disposalASX
US Medicare PDAC registration approvedMar 30, 2016Other filingsASX
30% growth of direct sales revenues of Somnodent devicesFeb 11, 2016Other filingsASX
SomnoMed exceeds 250,000 patientsFeb 10, 2016Other filingsASX
Growth acceleration in the US leads to new record quarterFeb 10, 2016Other filingsASX
FDA approves SomnoDent wearable compliance micro-recordingFeb 10, 2016Other filingsASX
SomnoMed to acquire 100% of SMH Biomaterial AGFeb 10, 2016Acquisition or disposalASX
SomnoMed updateFeb 10, 2016Other filingsASX
Continuous growth of SomnoMed in third quarterFeb 10, 2016Other filingsASX
S&P DJ Indices Announces March Quarterly ReviewFeb 10, 2016Other filingsASX
SomnoMed exceeds 200,000 patientsFeb 10, 2016Other filingsASX
New records in September confirm guidanceFeb 10, 2016GuidanceASX
Share Purchase Plan Offer and RulesFeb 10, 2016FinancingASX
Share Placement and 2014 Share Purchase PlanFeb 10, 2016FinancingASX
New sales records in Q4 & increasing growth prospects14/15Feb 10, 2016Other filingsASX
SomnoMed takes over Italian DistributionFeb 10, 2016Other filingsASX
SomnoMed USA receives 510K for Somnodent FusionFeb 10, 2016Other filingsASX
SomnoMed starts business in Spain and PortugalFeb 10, 2016Other filingsASX
SomnoMed enters UK - Ireland marketFeb 10, 2016Other filingsASX
SomnoMed commences business in FinlandFeb 10, 2016Other filingsASX
SomnoMed achieves 28% volume growth in Q3Feb 10, 2016Other filingsASX
SomnoMed accelerates growth in Q2Feb 10, 2016Other filingsASX
SomnoMed exceeds 150,000 patients wordwideFeb 10, 2016Other filingsASX
SomnoMed expands in KoreaFeb 10, 2016Other filingsASX
SomnoMed posts strong cash positionFeb 10, 2016Other filingsASX
SomnoMed acquires Orthosleep19 in GermanyFeb 10, 2016Acquisition or disposalASX
SomnoMed breaks through 10,000 unit sales in 4th QuarterFeb 10, 2016Other filingsASX
Progress in USAFeb 10, 2016Other filingsASX
Strong European growth and new US management team in placeFeb 10, 2016Other filingsASX
SomnoMed delivers a record Second QuarterFeb 10, 2016Other filingsASX
SomnoMed acquires MAS NordicFeb 10, 2016Acquisition or disposalASX
Compliance measurement - exclusive agreement signedFeb 10, 2016Other filingsASX
Acquisition of Orthosom in France completedFeb 10, 2016Acquisition or disposalASX
Acquisition of 2nd largest oral appliance company in FranceFeb 10, 2016Acquisition or disposalASX
Partnership with Burkhart Dental SupplyFeb 10, 2016Other filingsASX
SomnoMed MATRx receives FDA 510(k) clearanceFeb 10, 2016Other filingsASX
Half Year Report and AccountsFeb 10, 2016Interim reportASX
SomnoMed Announces Sleep Apnea Management ProgramFeb 10, 2016Other filingsASX
Somnomed introduces new Medical productFeb 10, 2016Other filingsASX
Launch of new product line to treat Sleep BruxismFeb 10, 2016Other filingsASX

Open Filings

Cap table

Built by 6ix from Somnomed Limited’s releases

Common shares
219,768,253
Fully diluted
219,768,253

Fully diluted

LineShares
Common shares219,768,253

Share count over time

CountShares
Nov 22, 2026219,768,253

Open Cap table

Shareholders

StakeStakeSharesDateFiling
NAOS Substantial Holders referred to in Annexure A.7.36%16.2MNov 19, 2026Substantial holder notice (ASX forms 603, 604, 605)

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alison BellSales Manager | UK · Since at least Nov 4, 2026
Andrew PriceNon-Executive Director · Since at least Nov 5, 2026
Benjamin GiszNon-Executive Director · Since at least Nov 5, 2026
Guy RussoNon-Executive Chairman · Oct 16, 2026 – Oct 16, 2026 · Past
Karen BorgChief Executive Officer and Executive Director · Since at least Aug 18, 2026
Michael GordonNon-Executive Director · Since at least Nov 5, 2026
Terence FlitcroftCompany Secretary · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Somnomed Limited.